Palisade Bio Announces Topline Results from U.S. Phase 2 PROFILE Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions

Stock Information for Palisade Bio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Palisade Bio Inc.

Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and Ulcerative Colitis
Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases
Palisade Bio's AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit
Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108
Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108
Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025
Palisade Bio Participates in Virtual Investor "What This Means" Segment
Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC) 

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.